Last reviewed · How we verify
chemoradiotherapy Paclitaxel
Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from growing and dividing.
Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from growing and dividing. Used for Non-small cell lung cancer, Ovarian cancer, Breast cancer.
At a glance
| Generic name | chemoradiotherapy Paclitaxel |
|---|---|
| Also known as | Paclitaxel |
| Sponsor | Shandong Cancer Hospital and Institute |
| Drug class | Taxane |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel binds to tubulin, a protein that makes up microtubules, and prevents them from disassembling. This leads to the formation of stable microtubules that prevent the cell from entering the mitotic phase, ultimately causing cell cycle arrest and apoptosis in cancer cells.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
- Breast cancer
- Pancreatic cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Mucositis
- Alopecia
Key clinical trials
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer (PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma (PHASE2)
- TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers (PHASE1, PHASE2)
- A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (NA)
- A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring (NA)
- Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- chemoradiotherapy Paclitaxel CI brief — competitive landscape report
- chemoradiotherapy Paclitaxel updates RSS · CI watch RSS
- Shandong Cancer Hospital and Institute portfolio CI